Market Chameleon (Mon, 10-Aug 3:29 AM ET)
PRNewswire (Mon, 10-Aug 7:00 AM ET)
NextCure Provides Business Update and Reports Second Quarter 2026 Financial Results
Globe Newswire (Thu, 6-Aug 4:01 PM ET)
NextCure Shareholders Face Just 1.21% Ownership in New Avere Merger—Is This a Fair Deal?
Market Chameleon (Mon, 27-Jul 7:24 AM ET)
PRNewswire (Fri, 24-Jul 4:38 PM ET)
PRNewswire (Wed, 22-Jul 2:04 PM ET)
Are CRNX, VEEE, NXTC, TCBK Obtaining Fair Deals for their Shareholders?
PRNewswire (Tue, 21-Jul 2:51 PM ET)
Globe Newswire (Tue, 21-Jul 7:39 AM ET)
PRNewswire (Tue, 14-Jul 1:34 PM ET)
Business Wire (Tue, 14-Jul 10:59 AM ET)
NextCure Inc is a clinical-stage biopharmaceutical company that is focused on advancing inventive medicines that treat cancer patients that do not respond to, or that have disease progression on, current therapies, through the use of targeted therapies including antibody-drug conjugates. The company's product candidates include NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
Nextcure trades on the NASDAQ stock market under the symbol NXTC.
As of October 7, 2026, NXTC stock price climbed to $6.56 with 108,552 million shares trading.
NXTC has a beta of 3.03, meaning it tends to be more sensitive to market movements. NXTC has a correlation of 0.04 to the broad based SPY ETF.
NXTC has a market cap of $30.03 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, NXTC traded as high as $30.84 and as low as $1.55.
The top ETF exchange traded funds that NXTC belongs to (by Net Assets): VTI, VXF, IWC, DFMC, DFAC.
NXTC has underperformed the market in the last year with a return of +9.3%, while SPY returned +16.9%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in NXTC shares. However, NXTC has outperformed the market in the last 3 month and 2 week periods, returning +216.9% and +26.6%, while SPY returned +3.7% and +0.5%, respectively. This indicates NXTC has been having a stronger performance recently.
NXTC support price is $5.25 and resistance is $6.12 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NXTC shares will trade within this expected range on the day.
